Albany, NY -- (SBWIRE) -- 08/30/2016 -- Venous thromboembolism (VTE) is a blood clot of the circulatory system and leads to obstructed blood flow. Although it can occur at any age, venous thromboembolism is commonly found in people aged 60 years and above and in adults. VTE is a preventable and a serious condition in people who have gone through a recent surgery. Deep vein thrombosis occurs when there is a blood clot in deep veins whereas pulmonary embolism occurs when deep vein thrombosis breaks off. Undergoing a surgery in itself raises the risk of VTE, states a new report added by MarketResearchReports.biz to its repository of research reports.

View Press Release at http://www.marketresearchreports.biz/pressrelease/2246

The report, titled "EpiCast Report: Venous Thromboembolism - Epidemiology Forecast To 2025" provides details so as to which patient subgroups will have the largest impact on VTE sales and which are the most commonly prescribed therapies for VTE patients. The impact of the approval of antidotes on novel oral anticoagulant drug class is also studied in the report. The market for VTE is predicted to witness a significant growth during the period between 2015 and 2025 owing to a reduction in the approval period of antidotes for novel oral anticoagulant drugs. The past few years have also seen a rise in physician acceptance of these drugs, which is driving the global market.

The analysts brief readers about various risk factors and historical and global trends for VTE in France, the U.S., Spain, China, Japan, Italy, and Germany.

VTE is one of the most commonly prevalent cardiovascular disease in the world. The high occurrence of this disease is fueling the demand for VTE treatment. An increasing awareness of the availability of various treatments for VTE is also encouraging the market to grow. However, stringent government approvals are predicted to restrict the approvals of VTE treatments, thus is expected to hamper the growth of the market.

For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/785534

As per the findings of the report, the diagnosed incident cases of VTE in 8MM are expected to increase from 1,116,358 cases in 2015 to 1,354,846 by 2025, at a AGR of 2.14% from 2015 to 2025. In 2015, 8MM had 314,886 diagnosed incident cases of pulmonary embolism and this number is expected to reach 377,612 by 2025 at a 1.99% AGR from 2015 to 2025. As per the report, the diagnosed incident cases of deep vein thrombosis in 8MM will increase from 801,472 cases in 2015 to 977,234 cases by 2025, at a 2.19% AGR from 2015 to 2025. Additionally, the report also forecasts that the total number of medically ill people at risk of venous thromboembolism in 8MM will increase from 44,611 in 2015 to 54,143,874 by 2025.

The total number of revision procedures and knee replacement procedures are predicted to shift from 1,532,360 in 2015 to 1,867,289 by 2025. The number of hip replacements is expected to shift from 1,220,965 in 2015 to 1,512,215 by 2025.